top of page

European Commission approves Biocon's Pebrilzo as first biosimilar under new tailored clinical approach

Immagine del redattore: nuaxia
nuaxia
7 minuti fa
Tempo di lettura: 1 min

Biocon has secured European Commission marketing authorisation for Pebrilzo, its pertuzumab biosimilar, marking what the company describes as the first biosimilar approval under the EMA's tailored clinical approach.


Biocon announced on 18 November 2026 that the European Commission had authorised Pebrilzo, a biosimilar to Perjeta (pertuzumab), for specified HER2-positive breast cancer treatment settings following a positive CHMP opinion in September.


The European decision is a separate regulatory milestone from Pebrilzo's US FDA approval announced on 16 November and highlights the EMA's evolving evidence requirements for biosimilar development; the authorisation does not establish clinical superiority over Perjeta or confirm immediate commercial availability in every European market.

Field

Content

Company

Biocon

Medicine

Pebrilzo (pertuzumab biosimilar)

Reference Medicine

Perjeta

Regulatory Authority

European Commission

Approval Announcement

18 November 2026

Approval Type

EU biosimilar marketing authorisation

Therapeutic Area

Oncology

Indication

Specified HER2-positive breast cancer treatment settings

Molecular Target

HER2

Product Classification

Monoclonal antibody biosimilar

Regulatory Pathway

EMA tailored clinical approach

Regulatory Distinction

Described by Biocon as the first biosimilar approved under the new tailored clinical approach

Earlier EU Milestone

Positive CHMP opinion in September 2026

Separate US Milestone

FDA approval announced 16 November 2026

Clinical Interpretation

Biosimilar approval does not establish superiority over the reference medicine

Commercial Implications

EU marketing authorisation enables potential market entry subject to applicable access and commercial arrangements

Primary Source

https://www.biocon.com/biocons-pertuzumab-gets-marketing-authorization-in-eu-first-biosimilar-approved-under-new-tailored-clinical-approach/


Discover how nuaxia can support your next medical education initiative:

 
 
 

Commenti

Valutazione 0 stelle su 5.
Non ci sono ancora valutazioni

Aggiungi una valutazione
bottom of page